
RIVOLTA ILARIA
- U08, Piano: 3, Stanza: L3.10B
- U08, Piano: 3, Stanza: 3037
Pubblicazioni
Frosio, A., Calamaio, S., Pagliarani, S., Cirillo, F., Melgari, D., Prevostini, R., et al. (2026). Integrated electrophysiological, cellular, and pharmacological profiling reveals variant-specific mechanisms in SCN4A-related myotonia. BIOMÉDECINE & PHARMACOTHÉRAPIE, 200(July 2026) [10.1016/j.biopha.2026.119625]. Dettaglio
Calamaio, S., Prevostini, R., Redaelli, S., Villa, M., Collo, G., Cavalleri, L., et al. (2026). Derivation and characterization of a patient-derived hiPSC line carrying the HCN2 p.G460D variant with neuronal and cardiac differentiation potential. FRONTIERS IN PHARMACOLOGY, 17 [10.3389/fphar.2026.1927604]. Dettaglio
Calamaio, S., Frosio, A., Melgari, D., Broggini, L., Sonzini, F., Prevostini, R., et al. (2026). Exploring light chain cardiotoxicity in AL amyloidosis: Impact on hiPSC-derived Cardiomyocyte Activity. AMYLOID [10.1080/13506129.2026.2686787]. Dettaglio
Giussani, C., Carrabba, G., Rivolta, I., Lober, R., Remida, P., Mazzoleni, F., et al. (2026). Venous dominance and systemic hemodynamic divergence in a coupled craniopagus circulation. BRAIN AND SPINE, 6 [10.1016/j.bas.2026.106275]. Dettaglio
Melgari, D., Calamaio, S., Frosio, A., Prevostini, R., Malacrida, A., Anastasia, L., et al. (2026). Electrophysiological mechanisms behind the differential cardiotoxicity of chemotherapeutic agents Bortezomib and Carfilzomib. FRONTIERS IN DRUG DISCOVERY, 6, 1-14 [10.3389/fddsv.2026.1774061]. Dettaglio